Cell Therapeutics news from FierceBiotech
News
Cell Therapeutics gets crucial cash infusion
Seattle-based Cell Therapeutics got a much-needed financial shot in the arm just days after filing SEC papers that indicated CTI needed new money to continue operations. Cell Therapeutics announced Read more...
Cell Therapeutics running out of cash
Seattle-based Cell Therapeutics is sending out an SOS signal to investors. "We have an immediate need to raise additional capital in the next thirty days in order to meet our operation needs," the Read more...
Limerick raises $15M; Icahn offered $15B for Biogen; Neogen expands R&D
> Limerick BioPharma has ginned $11 million in venture funds and borrowed $4 million more to advance its work on the bioavailability of drugs. Arch Venture Partners, Sevin Rosen Funds and Altitude Read more...
C&L: PDL BioPharma's L. Patrick Gage resigns
PDL BioPharma director and interim Chief Executive L. Patrick Gage resigned due to differences among the board about prioritizing company goals. Histogenics has named F. Ken Andrews president and Read more...
ALSO NOTED: Shire nabs orphan product; New prez at Cell Therapeutics; and much more...
> Shire has acquired arylsulfatase, an orphan enzyme replacement therapy in Phase I/II for Metachromatic Leukodystrophy, from the Danish company Zymenex. Read more...
Cell Therapeutics reorganizes, scales back R&D
Cell Therapeutics is scaling back its research plans for Xyotax and pixantrone, cutting one group of Read more...
ALSO NOTED: Osiris inks $224M contract; Baxter and Nektar to collaborate;and much more...
> Osiris Therapeutics has inked a deal with the U.S. Defense Department to supply a potential $224 million worth of Prochymal for use in treating military personnel exposed to radiation. Read more...
ALSO NOTED: AstraZeneca completes cancer study enrollment; Smallpox vaccine success triggers milestone; and much more...
> Here's a good estimate of how much it costs when a drug goes into free-fall: $440 million. That's how much Johnson & Johnson is writing off on Natrecor, a heart failure treatment that went Read more...
ALSO NOTED: Zingo data lifts Anesiva stock; Two chemo drugs win approvals; BrainStorm plans trials; and much more...
> Shares of Anesiva jumped after the company announced positive top-line data from a late-stage study of Zingo, its drug candidate for reducing venous procedural pain. Read more...
ALSO NOTED: Cell Therapeutics to bypass interim analysis; Nabi reports NicVAX data; Chinese see value in scientific failure; an
> Cell Therapeutics has decided to bypass an interim analysis of its non-Hodglin's lymphoma drug candidate Pixantrone. Instead, researchers say they will conduct a full analysis after the trial Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets